The U.S. House passed the country's annual defense policy bill, the $895 billion National Defense Authorization Act that includes a pay raise for service members and a funding ban on gender-affirming ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

"This is a very accelerated timeline," said one alderman. "Moving legislation so fast like this, we just want to make sure we're doing the right thing." ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...

Qure has reached an agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130, its gene therapy treatment aimed at Huntington’s disease.

UniQure (NASDAQ:QURE) stock shot up 90% Tuesday morning on news that the company had reached an agreement with the FDA on key elements for an accelerated approval pathway for its drug AMT-130 in the ...

UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for ...

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...